- Home
- TLRY vs AUTL Comparison
TLRY vs AUTL Comparison
Compare TLRY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- AUTL
- Stock Information
- Founded
- TLRY N/A
- AUTL 2014
- Country
- TLRY Canada
- AUTL United Kingdom
- Employees
- TLRY N/A
- AUTL N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLRY Health Care
- AUTL Health Care
- Exchange
- TLRY Nasdaq
- AUTL Nasdaq
- Market Cap
- TLRY 624.7M
- AUTL 625.4M
- IPO Year
- TLRY 2018
- AUTL 2018
- Fundamental
- Price
- TLRY $1.12
- AUTL $1.38
- Analyst Decision
- TLRY Buy
- AUTL Strong Buy
- Analyst Count
- TLRY 4
- AUTL 5
- Target Price
- TLRY $1.58
- AUTL $9.12
- AVG Volume (30 Days)
- TLRY 68.6M
- AUTL 4.4M
- Earning Date
- TLRY 10-09-2025
- AUTL 11-11-2025
- Dividend Yield
- TLRY N/A
- AUTL N/A
- EPS Growth
- TLRY N/A
- AUTL N/A
- EPS
- TLRY N/A
- AUTL N/A
- Revenue
- TLRY $821,309,000.00
- AUTL $29,934,000.00
- Revenue This Year
- TLRY $7.44
- AUTL $634.25
- Revenue Next Year
- TLRY $4.66
- AUTL $93.16
- P/E Ratio
- TLRY N/A
- AUTL N/A
- Revenue Growth
- TLRY 4.10
- AUTL 185.17
- 52 Week Low
- TLRY $0.35
- AUTL $1.11
- 52 Week High
- TLRY $1.88
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TLRY 52.38
- AUTL 28.28
- Support Level
- TLRY $1.03
- AUTL $1.34
- Resistance Level
- TLRY $1.22
- AUTL $1.46
- Average True Range (ATR)
- TLRY 0.11
- AUTL 0.09
- MACD
- TLRY -0.04
- AUTL 0.01
- Stochastic Oscillator
- TLRY 18.10
- AUTL 9.09
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. USA exposure consists of CBD products and alcohol.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.